Skip to main content
Clinical Trials/NCT01847703
NCT01847703
Completed
Not Applicable

Randomized Trial Comparing Robotic and Abdominal Surgery for High Risk Endometrial Cancer

Karolinska Institutet1 site in 1 country120 target enrollmentApril 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Neoplasms
Sponsor
Karolinska Institutet
Enrollment
120
Locations
1
Primary Endpoint
Number of harvested lymph nodes
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study is intended to explore differences in oncologic and surgical safety between robotic assisted laparoscopy and conventional abdominal surgery for high risk endometrial cancer.

Detailed Description

Hypothesis: Robotic assisted laparoscopy (RAL)is equal in terms of oncologic and surgical safety as conventional abdominal surgery (AS) for high risk endometrial cancer (EC). Methods: Women with high risk EC (defined as high grade endometrial, clear cell or serous) are randomized to either RAL or AS. Both groups will undergo complete surgical staging (hysterectomy, bilateral salpingoophorectomy, pelvic and paraaortal lymphadenectomy) Primary endpoint: Number of harvested lymph nodes per station Secondary endpoints: Recurrences up to 3 year after surgery. Lymphatic side-effects, quality of life, cost, surgical morbidity.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
July 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Henrik Falconer

MD, PhD

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • 18-75 years of age
  • High risk endometrial cancer

Exclusion Criteria

  • WHO performance\>1
  • Severe comorbidity, ASA\>3
  • Unable to understand information

Outcomes

Primary Outcomes

Number of harvested lymph nodes

Time Frame: 2 years

Extracted lymphatic tissue from 3 stations (above inferior mesenteric artery, below inferior mesenteric artery, pelvic) is analysed by a pathologist and the number of nodes for each station recorded and compared between the two groups

Secondary Outcomes

  • Lymphatic side-effects(2 years)
  • Quality of life(2 years)
  • Healthcare cost(2 years)
  • Recurrence of cancer(3 years)

Study Sites (1)

Loading locations...

Similar Trials